| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Income (loss) before income tax | 34,274 | -19,181 | -18,045 | 6,785 |
| Income tax expense | 16,968 | 5,239 | 3,641 | 13,514 |
| Net income (loss) attributable to common stockholders | 17,306 | -24,420 | -21,686 | -6,729 |
| Net income (loss) attributable to common stockholders per common share basic (in dollars per share) | 0.06 | -0.08 | -0.07 | -0.02 |
| Net income (loss) attributable to common stockholders per common share diluted (in dollars per share) | 0.06 | -0.08 | -0.07 | -0.02 |
| Weighted average common shares outstanding - basic (in shares) | 308,468,423 | 308,254,256 | 307,689,207 | 304,690,596 |
| Weighted average common shares outstanding - diluted (in shares) | 310,433,494 | 308,254,256 | 307,689,207 | 304,690,596 |
AMICUS THERAPEUTICS, INC. (FOLD)
AMICUS THERAPEUTICS, INC. (FOLD)